Source - RNS
RNS Number : 6086M
14 October 2016

BTG plc: Notice of Results - Amendment


London, UK, 14 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that it will be releasing its unaudited interim results for the six months ended 30 September 2016 (the "Interim Results") on Tuesday 15 November 2016.



For further information contact:



FTI Consulting

Andy Burrows, VP Corporate & Investor Relations

Mo Noonan / Hanna Skeppner

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

+44 (0)20 3727 1000

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178


About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit:

This information is provided by RNS
The company news service from the London Stock Exchange